Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative analysis of the sensitivity and specificity of the classification criteria and correlation with prognosis of disease in patients with Systemic Lupus Erythematosus.
Adamichou C, Nikolopoulos D, Papastefanakis E, Kalogiannaki E, Gergianaki I, Kountouri A, Repa A, Avgoustidis N, Kougkas N, Sidiropoulos P, Fanouriakis A, Bertsias G. Adamichou C, et al. Among authors: kalogiannaki e. Mediterr J Rheumatol. 2018 Dec 18;29(4):232-235. doi: 10.31138/mjr.29.4.232. eCollection 2018 Dec. Mediterr J Rheumatol. 2018. PMID: 32185334 Free PMC article.
In an early SLE cohort the ACR-1997, SLICC-2012 and EULAR/ACR-2019 criteria classify non-overlapping groups of patients: use of all three criteria ensures optimal capture for clinical studies while their modification earlier classification and treatment.
Adamichou C, Nikolopoulos D, Genitsaridi I, Bortoluzzi A, Fanouriakis A, Papastefanakis E, Kalogiannaki E, Gergianaki I, Sidiropoulos P, Boumpas DT, Bertsias GK. Adamichou C, et al. Among authors: kalogiannaki e. Ann Rheum Dis. 2020 Feb;79(2):232-241. doi: 10.1136/annrheumdis-2019-216155. Epub 2019 Nov 8. Ann Rheum Dis. 2020. PMID: 31704720
Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study.
Bertsias A, Avgoustidis N, Papalopoulos I, Repa A, Kougkas N, Kalogiannaki E, Bertsias G, Flouri I, Sidiropoulos P. Bertsias A, et al. Among authors: kalogiannaki e. Arthritis Res Ther. 2022 Jun 2;24(1):132. doi: 10.1186/s13075-022-02826-6. Arthritis Res Ther. 2022. PMID: 35655317 Free PMC article.
Distinct long-term disease activity trajectories differentiate early on treatment with etanercept in both rheumatoid arthritis and spondylarthritis patients: a prospective cohort study.
Flouri I, Goutakoli P, Repa A, Bertsias A, Avgoustidis N, Eskitzis A, Pitsigavdaki S, Kalogiannaki E, Terizaki M, Bertsias G, Sidiropoulos P. Flouri I, et al. Among authors: kalogiannaki e. Rheumatol Int. 2024 Feb;44(2):249-261. doi: 10.1007/s00296-023-05455-7. Epub 2023 Oct 10. Rheumatol Int. 2024. PMID: 37815625 Free PMC article.
Comorbidities Burden and Implementation of the Treat-to-Target Strategy in Predicting Real-World Patient Outcomes in Spondyloarthritides.
Flouri ID, Repa A, Avgoustidis N, Pitsigavdaki S, Pateromichelaki K, Marolachaki E, Terizaki M, Nikoloudaki M, Eskitzis A, Kalogiannaki E, Bertsias G, Sidiropoulos P. Flouri ID, et al. Among authors: kalogiannaki e. Mediterr J Rheumatol. 2023 Jul 31;34(4):581-587. doi: 10.31138/mjr.310723.cba. eCollection 2023 Dec. Mediterr J Rheumatol. 2023. PMID: 38282943 Free PMC article.
A Peripheral Blood Signature of Increased Th1 and Myeloid Cells Combined with Serum Inflammatory Mediators Is Associated with Response to Abatacept in Rheumatoid Arthritis Patients.
Goutakoli P, Papadaki G, Repa A, Avgoustidis N, Kalogiannaki E, Flouri I, Bertsias A, Zoidakis J, Samiotaki M, Bertsias G, Semitekolou M, Verginis P, Sidiropoulos P. Goutakoli P, et al. Among authors: kalogiannaki e. Cells. 2023 Dec 9;12(24):2808. doi: 10.3390/cells12242808. Cells. 2023. PMID: 38132128 Free PMC article.